Technology:

1
UK Manufacturing Strategy Progress check - One
Year On NESTA, London

• Technology
• High Value Manufacturing

Robin Wilson Lead Technologist, High Value
Manufacturing 29th October 2009
2
(No Transcript)
3
Who are the Technology Strategy Board

• We are a national body set up to invest in
  business innovation
• We are sponsored by Department of Business,
  Innovation and Skills (BIS our hosts today)
• We come from business (and the public sector)
• About 100 people, gt1200 years of business
  experience
• We work across business, universities and
  Government
• We are responsible for investing 1bn

4
We support the full range of business

• We help strengthen the global competitive
  position of our leading businesses
• We identify and grow sectors and businesses with
  the capacity to become the best in the world
• We nurture the businesses that can succeed in the
  growth sectors of tomorrow

5
And we make choices

• We dont pick winners, we pick sectors where UK
  businesses can thrive and support innovative
  companies in them
• We consider the size of the markets, the
  capability of the UK to address them and the
  timing
• And the difference our support would make

6

How we deliver
7
Technology Inspired Innovation

• We build capability in the underpinning areas
  that enable a sure and effective response to
  market needs
• Advanced materials
• Bioscience
• Electronics, photonics and electrical systems
• Information and communication technologies
• High value manufacturing
• Nanotechnology

8
Our Tools for Prioritisation and Delivery

• Published Technology Strategies
• To communicate funding priorities and rationale
• eg High Value Manufacturing Strategy (Sept 2008)
• To provide clear, consistent focus for funding
  applicants
• Competitions collaborative RD projects
• eg 24m High Value Mfg, launched January 2009
• Additional funding mechanisms
• SBRI for RD contracts (Government procurement)
• Large (gt5m) CRD Projects, assessed on
  individual basis

9
Our Investment (Assessment) criteria
Model for success a convincing yes to these 4
questions
10
Manufacturing Strategy

• Working with Industry
• Working with Academia
• Working with Government
• Working together
• Developing a common understanding of challenges
  and opportunities
• Prioritising investment in key areas
• Publish Strategy, launch CRD competitions

11
ManufacturingThrough Life

• Not just production
• Interfaces forwards and backwards

HIGH VALUE MANUFACTURING
Research
Production
Service
Decommission
Design Development
Sale
Operation
12
We are worlds 6th largest manufacturer
13
The Four Pillars of the HVM Strategy
The strategy includes key manufacturing
activities that enhance competitive advantage in
high wage economies and it recognises that
large amounts of value-add and value-capture
occur outside production and that technology
may bring innovation in all areas.
14
Prioritisation .. in areas of high growth high
RD intensity
RD Intensity
Growth
15
High Value Manufacturing Competition

• The Step Change in Competitiveness / Value
  Systems Competition was launched in January 2009
  and invited businesses in a broad range of
  industry sectors to form consortia and compete
  for funding.
• The aim was for companies to achieve major
  improvements of between 25 and 50 relative to
  their current performance in areas such as
  overall manufacturing costs, whole life-cycle
  costs, whole life environmental impact and
  product performance, durability and reliability. 

16
January 09 Competition - metrics

• 24M Step Change in Competitiveness and Value
  Systems
• Your Response
• 500 downloads (enquiries)
• 300 EoIs (gt300M investment requested)
• 87 Full Proposals assessed
• 32 projects shortlisted for funding

17
And the results how the 24m was won
18
Some of the Winning Consortia here today at
NESTA

• SHIELD Project
• Simon Collins
• Pete Ellison
• Tom Pinto
• Venu Kumar    
• BIOCHEMIST Project
•  Kay McClean
• CELL THERAPIES Project
• Tina Crombie
•  

 HEPTACORE Project  Mike Whelan   RAPIDPART 
Project Russell Owen, Weir Valves Peter Brown,
TWI STEP Project Keith Freebairn  Professor Ian
Sutherland
19
Discussion

• Consortia members you are our customers !
• Customer satisfaction?
• How did you hear about the competition?
• Is the subject scope (technology) right for you?
• Funding and timescales?
• What do we (TSB BIS) do right?
• What could we improve on?
• Other contributions feedback?

20
SHIELD

• Summary The aim of project SHIELD is to develop
  novel acetabular and femoral components that
  minimise bone resorption. This will be achieved
  through a combination of component design and
  material optimisation by which the load transfer
  from prosthesis to bone will attempt to mimic
  bone stress levels pre-operation. The objective
  is to develop an innovative solution to the
  problem of stress shielding in hip implants
  therefore increasing the efficacy of total hip
  prostheses by increased life span and a reduced
  need for revision surgery after failed
  implantation.
• Partners
• Corin Ltd (lead),
• Invibio Biomaterial Solutions Ltd,
• Durham University
• TWI Ltd,
• Imorphics Ltd,
• Continuum Blue Ltd.

21
BIOCHEMIST

• Title Biocatalysis and Chemical Engineering for
  Manufacturing Intensification and Sustainability
  - BIOCHEMIST
• Summary This project will integrate all phases
  of bioprocess development from catalyst discovery
  and engineering, to process design, through to
  highly efficient small footprint manufacture of
  high value products - enhancing the efficiency,
  sustainability and flexibility of chemical
  manufacture. The principle objectives of the
  project are (a) a novel compact reactor system
  for efficient continuous chemical manufacture,
  (b) advanced process design to accelerate
  introduction of new bio-manufacturing processes
  and products (c) new competitive bioprocesses to
  prepare unnatural amino acids and chiral amines.
• Partners
• C -Tech Innovation Ltd (lead),
• Ashe Morris Ltd,
• Ingenza Ltd.

22
STEP

• Title Scalable Technology for the Extraction of
  Pharmaceuticals - STEP
• Summary We plan to develop small footprint,
  versatile, counter-current chromatography
  purification technology and methodology which can
  be operated at a range of scales in both batch
  and continuous modes and that can be inserted
  into existing process plant and systems. The
  consortium will address major production
  challenges aiming to provide a flexible, low
  capital capability driving substantial cost
  efficiency in both drug development and drug
  manufacturing processes.
• Partners
• GlaxoSmithKline Research and Development Ltd
  (lead)
• Brunel University
• Pfizer Limited
• Dynamic Extractions Ltd.

23
MANUFACTURE OF CELL THERAPIES

• Title Advanced manufacturing process for the
  production of individualised cell therapies
• Summary Individualised cell therapies ("ICTs")
  for the treatment of cancer, autoimmune disease,
  and infectious disease are progressing through
  regulatory approval for clinical use. ICTs are
  generally based on natural or genetically
  enhanced immune cells with disease-fighting
  applications and are therefore distinct from
  regenerative stem cell therapies. This project
  aims to achieve the first advanced cell
  manufacturing system (the "CellPro Manufacturing
  System") to support the routine clinical use of
  ICTs on a cost-effective and convenient basis.
  
• Partners
• Cell Medica Ltd (lead)
• University College London,
• eXmoor pharma concepts ltd.

24
RAPIDPART

• Title RapidPart - Significant Step Change in the
  Selective Laser Melting Powder Bed Process for
  the Manufacture of High Value Components
• Summary RapidPart will deliver step change
  reductions in the manufacturing cost of laser
  powder bed deposition, or Selective Laser Melting
  (SLM), by significantly increasing the speed of
  the process. The targeted 500 increase in
  processing speed will enable this high value,
  flexible and environmentally-friendly process to
  become commercially viable for a more widespread
  range of applications, giving the UK a technical
  advantage and world lead in laser additive
  manufacture.
• Partners
• Weir Valves and Controls UK Ltd (lead)
• TWI Ltd (Academic)
• Thinklaser Limited,
• MTT Technologies Ltd,
• SPI Lasers UK Limited
• Disenco Limited,
• Materialise UK.

25
HEPTACORE

• Title Commercial manufacture of a novel dual
  hepatitis vaccine (Hepatacore)
• Summary The aim of this project is the further
  development and commercial manufacture of a
  tandem-core technology (TCT) vaccine candidate,
  such that a clinical trial may be undertaken.
  TCT allows the insertion of at least two
  different viral antigens into a single highly
  immunogenic recombinant protein. This results in
  a vaccine which can deliver immunity to two
  viruses simultaneously within the confines of a
  single construct. This project intends to
  manufacture commercially a combined hepatitis A
  and B vaccine (HAV/HBV).
• Partners
• iQur Ltd
• University College London
• Mologic Ltd.

26
(No Transcript)
27
Helping you stay competitive

• Manufacturing Strategy
• We believe our September 2008 HVM strategy (and
  the Governments Manufacturing Strategy published
  at the same time) remain valid and relevant, in
  recession and for recovery.
• Additional Funding
• 150m Advanced Mfg package (July, Govt)
• 5m extension to HVM competition (July, TSB)
• 1m Technology Inspired Feasibility (Sept, TSB)
• Further TSB competitions with significant
  manufacturing content planned for 2010.

28
http//www.innovateuk.orge robin.wilson_at_tsb.gov
.ukt 01793 442938